Ophthalmic therapeutic composition

Abstract

An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1)(Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH 2 , which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

1 . An ophthalmological composition, containing, as an effective component, the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug.  
     
     
         2 . Either or both of a corneal disorder preventive agent and a corneal disorder treatment agent, having, as an effective component, the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug.  
     
     
         3 . Either or both of the corneal disorder preventive agent and the corneal disorder treatment agent according to  claim 2 , with which the corneal disorder is corneal ulcer, corneal epithelial erosion, keratitis, or dry eye.  
     
     
         4 . Either or both of the corneal disorder preventive agent and the corneal disorder treatment agent according to  claim 2 , wherein the dosage form is an ophthalmic formulation.  
     
     
         5 . Either or both of the corneal disorder preventive agent and the corneal disorder treatment agent according to  claim 3 , wherein the dosage form is an ophthalmic formulation.  
     
     
         6 . A corneal epithelium migration promoting agent having, as an effective component, the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug.  
     
     
         7 . The corneal epithelium migration promoting agent according to  claim 6 , wherein the dosage form is an ophthalmic formulation.  
     
     
         8 . Usage of an effective amount of the peptide, PHSRN (SEQ ID NO: 1), or a salt of this peptide that is allowable as a medical drug and a corneal disorder treatment method based on such usage.